Horizon Therapeutics Q2 Adj. EPS $1.20 Beats $1.12 Estimate, Sales $945.00M Beat $915.60M Estimate
Portfolio Pulse from Benzinga Newsdesk
Horizon Therapeutics (NASDAQ:HZNP) reported Q2 earnings of $1.20 per share, beating the analyst consensus estimate of $1.12 by 7.14%. This is a 12.15% increase from the same period last year. The company also reported quarterly sales of $945.00 million, beating the analyst consensus estimate of $915.60 million by 3.21%, a 7.83% increase from the same period last year.
August 08, 2023 | 11:01 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Horizon Therapeutics reported better than expected Q2 earnings and sales, which could positively impact its stock price.
Horizon Therapeutics reported Q2 earnings and sales that beat analyst estimates. This positive financial performance is likely to increase investor confidence and could lead to a rise in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100